Financials Medios AG

Equities

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra 09:06:13 29/04/2024 pm IST 5-day change 1st Jan Change
14.28 EUR +0.14% Intraday chart for Medios AG +0.85% -9.96%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 384.5 601.6 787.3 400.4 377.6 339.9 - -
Enterprise Value (EV) 1 375.1 601 668.6 342.4 377.6 502.4 377.8 414.8
P/E ratio 40.6 x 95.9 x 105 x 22.7 x 20.1 x 12 x 10.4 x 8.28 x
Yield - - - - - - - -
Capitalization / Revenue 0.74 x 0.96 x 0.58 x 0.25 x 0.21 x 0.17 x 0.16 x 0.15 x
EV / Revenue 0.73 x 0.96 x 0.49 x 0.21 x 0.21 x 0.25 x 0.18 x 0.18 x
EV / EBITDA 22.9 x 39.8 x 17.4 x 6.24 x 6.24 x 6.07 x 3.98 x 3.55 x
EV / FCF -148 x -14.7 x 13 x 10.7 x - 12.3 x 7.63 x 7.72 x
FCF Yield -0.68% -6.79% 7.72% 9.36% - 8.13% 13.1% 13%
Price to Book 4.71 x 4.22 x 2.26 x 0.93 x - 0.73 x 0.68 x 0.65 x
Nbr of stocks (in thousands) 14,564 16,085 20,265 22,881 23,806 23,806 - -
Reference price 2 26.40 37.40 38.85 17.50 15.86 14.28 14.28 14.28
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 516.8 626.5 1,357 1,611 1,785 2,020 2,114 2,263
EBITDA 1 16.37 15.1 38.44 54.88 60.51 82.73 95 116.7
EBIT 1 14.39 9.542 15.26 28.97 31.37 52.83 64.35 73.9
Operating Margin 2.78% 1.52% 1.12% 1.8% 1.76% 2.62% 3.04% 3.27%
Earnings before Tax (EBT) 1 14.22 8.901 13.58 27.82 29.37 43.4 58.33 64.95
Net income 1 9.76 6.064 7.402 18.33 18.81 29.54 39.59 44.05
Net margin 1.89% 0.97% 0.55% 1.14% 1.05% 1.46% 1.87% 1.95%
EPS 2 0.6500 0.3900 0.3700 0.7700 0.7900 1.195 1.369 1.725
Free Cash Flow 1 -2.539 -40.84 51.62 32.06 - 40.85 49.5 53.75
FCF margin -0.49% -6.52% 3.8% 1.99% - 2.02% 2.34% 2.38%
FCF Conversion (EBITDA) - - 134.31% 58.42% - 49.38% 52.1% 46.06%
FCF Conversion (Net income) - - 697.39% 174.91% - 138.28% 125.02% 122.02%
Dividend per Share 2 - - - - - - - -
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 - 353.9 368.6 393 399.2 419.2
EBITDA 1 18.26 9.943 10.23 14.14 14.32 15.3
EBIT - - - - - -
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 - 5.418 - 7.588 - 8.594
Net income - - - - - -
Net margin - - - - - -
EPS 2 - - - 0.2100 - 0.2500
Dividend per Share - - - - - -
Announcement Date 12/08/21 09/11/21 29/03/22 11/05/22 11/08/22 10/11/22
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 162 37.8 74.9
Net Cash position 1 9.38 0.55 119 58 - - - -
Leverage (Debt/EBITDA) - - - - - 1.964 x 0.3982 x 0.6418 x
Free Cash Flow 1 -2.54 -40.8 51.6 32.1 - 40.9 49.5 53.8
ROE (net income / shareholders' equity) 12.8% 5.41% 2.76% 4.35% - 5.3% 6.93% 8.4%
ROA (Net income/ Total Assets) - - 2.06% 3.33% - 4.25% 4.68% -
Assets 1 - - 359.3 550.1 - 694.4 846.2 -
Book Value Per Share 2 5.600 8.850 17.20 18.80 - 19.40 21.10 22.10
Cash Flow per Share 2 - - 3.050 1.560 - 2.450 2.400 3.260
Capex 1 2.09 2.72 9.9 5.06 - 9.05 9.27 17.3
Capex / Sales 0.4% 0.43% 0.73% 0.31% - 0.45% 0.44% 0.76%
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.28 EUR
Average target price
34.75 EUR
Spread / Average Target
+143.35%
Consensus

Quarterly revenue - Rate of surprise